QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 eledon-pharmaceuticals-lead-asset-fails-in-mid-stage-study-but-pushes-forward-with-pivotal-study

Eledon shares drop as tegoprubart misses the main goal in Phase 2 kidney transplant trial, though safety signals and kidney fun...

 eledon-pharmaceuticals-phase-2-bestow-trial-shows-tegoprubart-maintains-strong-kidney-function-and-safety-supporting-phase-3-advancement-in-transplant-rejection-prevention

Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular ...

 hc-wainwright--co-reiterates-buy-on-eledon-pharmaceuticals-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy and maintains $9 price ta...

 eledon-pharma-q2-eps-013-beats-024-estimate

Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.24)...

 voyager-eledon-presents-data-from-phase-1b-trial-evaluating-tegoprubart-for-prevention-of-rejection-in-kidney-transplant-patients

Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² ...

 eledon-pharmaceutical-to-host-a-conference-call-and-webcast-on-wednesday-august-6-2025-to-discuss-updated-clinical-data-from-its-ongoing-open-label-phase-1b-study-evaluating-tegoprubart-for-the-prevention-of-rejection-in-subjects-undergoing-kidney-transplantation

IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced...

 craig-hallum-initiates-coverage-on-eledon-pharmaceuticals-with-buy-rating-announces-price-target-of-12

Craig-Hallum initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.

Core News & Articles

Sernova Biotherapeutics ("Sernova") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research A...

 hc-wainwright--co-assumes-eledon-pharmaceuticals-at-buy-announces-price-target-of-9

HC Wainwright & Co. analyst Yi Chen assumes Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price T...

 eledon-pharma-q1-eps-008-beats-030-estimate

Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.30)...

 eledon-pharma-fy-2024-gaap-eps-075-misses-064-estimate

Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.6...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION